Stifel started covering Definium Therapeutics Inc. (DFTX) on Thursday, and the analyst is pretty excited about what he sees. The big story here is DT120, the company's lead psychedelic-based therapy, and 2026 is shaping up to be the year that makes or breaks it. That's when we get the crucial Phase 3 trial results.
Definium, which used to be called MindMed, is in the business of developing psychedelic treatments for psychiatric and neurological disorders. And the timing might be interesting: on the same day as this initiation, reports surfaced that the U.S. government is preparing to take a closer look at ibogaine, another psychedelic substance used abroad for conditions like PTSD. It's part of a broader effort to evaluate its safety and potential medical value.
Analyst Paul Matteis made it clear that the upcoming topline data from the Phase 3 trials of DT120 will be everything for the company's future. Results are expected in mid-2026 for generalized anxiety disorder (GAD) and major depressive disorder (MDD). DT120, previously known as MM120, is an orally disintegrating tablet formulation of lysergide D-tartrate (LSD) designed with fast-dissolve technology.
Stifel's investment thesis leans heavily on DT120's probability of success in GAD, with data anticipated in the early third quarter of 2026. The analyst described GAD as a major "white space" in neuropsychiatry, where even modest market penetration could translate into a multi-billion-dollar opportunity. For MDD, the outlook is viewed as somewhat riskier, but Matteis noted that DT120 still has a credible chance of success, with data expected in the late second quarter of 2026.
On the clinical side, Stifel pointed to encouraging Phase 2b data and additional investigator-sponsored studies supporting DT120's efficacy in anxiety. Now, LSD comes with some baggage—it's historically been an illicit substance. But emerging clinical evidence suggests therapeutic potential. On safety, the analyst acknowledged LSD's reputation as less "clean" compared to other psychedelics like psilocybin, but added that DT120's current safety profile appears relatively benign. Key opinion leaders have largely expressed limited concern based on available data.
Matteis initiated with a Buy rating and a price forecast of $30. Stifel also argued that the broader psychedelics space remains undervalued, even as Definium holds one of the largest market capitalizations among peers. The firm expects multiple companies in the sector to succeed, with Definium positioned as a leading contender.
Financially, the company is sitting pretty for now. Definium reported $411.6 million in cash, cash equivalents, and investments as of December 31, 2025, which is expected to fund operations into 2028.
As for the stock, Definium Therapeutics shares were up 0.89% at $22.86 at the time of publication on Friday. The stock is approaching its 52-week high of $23.41.
